27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- BMO Capital Markets has raised the price target on Beam Therapeutics Inc (NASDAQ:BEAM) to $61 from $41, with a Market Perform rating unchanged.
- The model changes include updated collaboration revenues for Verve Therapeutics Inc's (NASDAQ:VERV) VERVE-101 program and the incorporation of the Alpha-1 antitrypsin deficiency (AATD) program, modeled at ~$1 billion peak risk-adjusted sales in 2035E.
- Related: Verve Therapeutics Amends Gene Editing Pact With Beam Therapeutics.
- BMO says that the key points Beam's thesis continues to rely on:
- Beam's gene editing platform is differentiated preclinically, with best-in-class potential, but clinical derisking is yet to be established.
- Penetration of Beam's lead assets in the Sickle Cell Disease (SCD) market may be limited given that key competitors are ~3+ years ahead.
- Diversified pipeline/partnerships can offer long-term optionality.
- Related: BMO Capital Says Risk/Reward For This Gene Stock Assumes Clinical Success.
- The analyst agrees that Beam's AATD and BEAM-102 programs can ultimately be commercially competitive but believe that the underlying risk due to their early stage of development doesn't allow for a high valuation.
- Price Action: BEAM shares are up 5.15% at $60.59 during the market session on the last check Monday
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!